Across TCGA pan-cancer cohorts, IGHV3-11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV3-11 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGHV3-11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGHV3-11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where IGHV3-11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.912	0.452	.010	18	view →
LUAD	OS	Median	III,IV	0.330	0.861	<.001	17	view →
GBM	DFS	Median	All	0.249	0.493	.009	3	view →
UCEC	OS	Tertile	All	0.733	1.000	.038	2	view →
HNSC	DFS	Quartile	All	0.568	0.939	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV3-11 tumor-vs-normal RNA expression · all IGHV3-11 data types